BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu Y, Muo C, Liu C, Tsai W, Hsu C, Sung F, Kao C. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: A 9-year population-based cohort study. Journal of Hepatology 2015;62:519-25. [DOI: 10.1016/j.jhep.2014.09.022] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Gadallah M, Kandil S, Mohsen A. Association between hepatitis C infection and cerebro-cardiovascular disease: analysis of a national population-based survey in Egypt. Trop Med Int Health 2018;23:738-47. [PMID: 29723920 DOI: 10.1111/tmi.13068] [Reference Citation Analysis]
2 Chew KW, Bhattacharya D, Horwich TB, Yan P, McGinnis KA, Tseng C, Freiberg MS, Currier JS, Butt AA. Performance of the Pooled Cohort atherosclerotic cardiovascular disease risk score in hepatitis C virus-infected persons. J Viral Hepat 2017;24:814-22. [PMID: 28273386 DOI: 10.1111/jvh.12705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
3 Goossens N, Negro F. Cardiovascular Manifestations of Hepatitis C Virus. Clin Liver Dis 2017;21:465-73. [PMID: 28689586 DOI: 10.1016/j.cld.2017.03.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
4 Ilyas SZ, Tabassum R, Hamed H, Rehman SU, Qadri I. Hepatitis C Virus-Associated Extrahepatic Manifestations in Lung and Heart and Antiviral Therapy-Related Cardiopulmonary Toxicity. Viral Immunol 2017;30:633-41. [PMID: 28953449 DOI: 10.1089/vim.2017.0009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
5 Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10:415-423. [PMID: 26660706 DOI: 10.1007/s12072-015-9684-3] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 12.8] [Reference Citation Analysis]
6 West-Livingston LN, Dittman JM, Park JA, Pascarella L. Sexual orientation, gender identity, and gender expression: From current state to solutions for the support of lesbian, gay, bisexual, transgender, and queer/questioning patients and colleagues. J Vasc Surg 2021;74:64S-75S. [PMID: 34303461 DOI: 10.1016/j.jvs.2021.03.057] [Reference Citation Analysis]
7 Petta S. Hepatitis C virus and cardiovascular: A review. J Adv Res 2017;8:161-8. [PMID: 28149651 DOI: 10.1016/j.jare.2016.06.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
8 Hsu YH, Hung PH, Muo CH, Tsai WC, Hsu CC, Kao CH. Interferon-Based Treatment of Hepatitis C Virus Infection Reduces All-Cause Mortality in Patients With End-Stage Renal Disease: An 8-Year Nationwide Cohort Study in Taiwan. Medicine (Baltimore). 2015;94:e2113. [PMID: 26632730 DOI: 10.1097/md.0000000000002113] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 3.6] [Reference Citation Analysis]
9 Al-rabadi L, Box T, Singhania G, Al-marji C, Agarwal A, Hall I, Gordon CE, Tran H. Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates: HCV treatment in ESRD patients. Hemodialysis International 2018;22:S45-52. [DOI: 10.1111/hdi.12656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Nevola R, Acierno C, Pafundi PC, Adinolfi LE. Chronic hepatitis C infection induces cardiovascular disease and type 2 diabetes: mechanisms and management. Minerva Med 2021;112:188-200. [PMID: 33205641 DOI: 10.23736/S0026-4806.20.07129-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Solis JG, Enciso López ES, Bautista Santos A, Anda Garay JC, Calixto Rodríguez JL, Moreno Alcántar R, Montiel López L. Effect of Direct Antiviral Agents on Atherosclerosis in Patients with Chronic Hepatitis C. Arch Med Res 2021:S0188-4409(21)00115-6. [PMID: 33972118 DOI: 10.1016/j.arcmed.2021.04.009] [Reference Citation Analysis]
12 Babiker A, Jeudy J, Kligerman S, Khambaty M, Shah A, Bagchi S. Risk of Cardiovascular Disease Due to Chronic Hepatitis C Infection: A Review. J Clin Transl Hepatol. 2017;5:343-362. [PMID: 29226101 DOI: 10.14218/jcth.2017.00021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
13 Domont F, Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver Int. 2016;36:621-627. [PMID: 26763484 DOI: 10.1111/liv.13064] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
14 Hu PJ, Chen CH, Wong CS, Chen TT, Wu MY, Sung LC. Influenza vaccination reduces incidence of peripheral arterial occlusive disease in elderly patients with chronic kidney disease. Sci Rep 2021;11:4847. [PMID: 33649465 DOI: 10.1038/s41598-021-84285-8] [Reference Citation Analysis]
15 Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Reference Citation Analysis]
16 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-9693. [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
17 Yao CW, Shen TC, Lu CR, Wang YC, Lin CL, Tu CY, Hsia TC, Shih CM, Hsu WH, Sung FC. Asthma Is Associated With a Subsequent Risk of Peripheral Artery Disease: A Longitudinal Population-Based Study. Medicine (Baltimore) 2016;95:e2546. [PMID: 26817901 DOI: 10.1097/MD.0000000000002546] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
18 Tan BK, Chalouni M, Ceron DS, Cinaud A, Esterle L, Loko MA, Katlama C, Poizot-Martin I, Neau D, Chas J, Morlat P, Rosenthal E, Lacombe K, Naqvi A, Barange K, Bouchaud O, Gervais A, Lascoux-Combe C, Garipuy D, Alric L, Goujard C, Miailhes P, Aumaitre H, Duvivier C, Simon A, Lopez-Zaragoza JL, Zucman D, Raffi F, Lazaro E, Rey D, Piroth L, Boué F, Gilbert C, Bani-Sadr F, Dabis F, Sogni' P, Wittkop L, Boccara F; ANRS CO13 HEPAVIH study group. Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. Clin Infect Dis 2021;72:e215-23. [PMID: 32686834 DOI: 10.1093/cid/ciaa1014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Petta S, Craxì A. Extrahepatic Manifestations of Chronic Viral C Hepatitis. Gastroenterol Clin North Am 2020;49:347-60. [PMID: 32389367 DOI: 10.1016/j.gtc.2020.01.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Carrero A, Berenguer J, Hontañón V, Navarro J, Hernández-Quero J, Galindo MJ, Quereda C, Santos I, Téllez MJ, Ortega E, Sanz J, Medrano LM, Pérez-Latorre L, Bellón JM, Resino S, Bermejo J, González-García J; GeSIDA 3603b Study Group. Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients. J Acquir Immune Defic Syndr 2020;83:292-300. [PMID: 31913996 DOI: 10.1097/QAI.0000000000002260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Beltrán LM, Rubio-Navarro A, Amaro-Villalobos JM, Egido J, García-Puig J, Moreno JA. Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus. Vasc Health Risk Manag 2015;11:35-48. [PMID: 25609975 DOI: 10.2147/VHRM.S65885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
23 Shahid I, AlMalki WH, Hassan S, Hafeez MH. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol 2018;44:143-60. [PMID: 28539069 DOI: 10.1080/1040841X.2017.1329277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Petta S, Adinolfi LE, Fracanzani AL, Rini F, Caldarella R, Calvaruso V, Cammà C, Ciaccio M, Di Marco V, Grimaudo S, Licata A, Marrone A, Nevola R, Pipitone RM, Pinto A, Rinaldi L, Torres D, Tuttolomondo A, Valenti L, Fargion S, Craxì A. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol 2018;69:18-24. [PMID: 29505844 DOI: 10.1016/j.jhep.2018.02.015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 19.3] [Reference Citation Analysis]
25 Hsu Y, Sung F, Muo C, Chuang S, Chen C, Hsu CY, Hsu C. Increased risk of developing peripheral artery disease in hemodialysis patients receiving statin treatments: a population-based cohort study in Taiwan. Nephrology Dialysis Transplantation 2020;35:1753-60. [DOI: 10.1093/ndt/gfz251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Alvaro-Meca A, Berenguer J, Díaz A, Micheloud D, Aldámiz-Echevarría T, Fanciulli C, Resino S. Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era. PLoS One 2017;12:e0179493. [PMID: 28617855 DOI: 10.1371/journal.pone.0179493] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
27 Petta S, Maida M, Macaluso FS, Barbara M, Licata A, Craxì A, Cammà C. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology. 2016;150:145-155.e4; quiz e15-16. [PMID: 26386298 DOI: 10.1053/j.gastro.2015.09.007] [Cited by in Crossref: 137] [Cited by in F6Publishing: 121] [Article Influence: 22.8] [Reference Citation Analysis]
28 Soriano V, Berenguer J. Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients: . Current Opinion in HIV and AIDS 2015;10:309-15. [DOI: 10.1097/coh.0000000000000175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
29 Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2017;66:344-56. [PMID: 28109003 DOI: 10.1002/hep.29071] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
30 Younossi ZM, Henry L, P. Ong J, Tanaka A, Eguchi Y, Mizokami M, Lim Y, Dan YY, Yu M, Stepanova M. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther 2019;49:644-53. [DOI: 10.1111/apt.15131] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
31 Mahale P, Engels EA, Li R, Torres HA, Hwang LY, Brown EL, Kramer JR. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. Gut. 2018;67:553-561. [PMID: 28634198 DOI: 10.1136/gutjnl-2017-313983] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 16.5] [Reference Citation Analysis]
32 Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV Extrahepatic Manifestations. J Clin Transl Hepatol. 2019;7:172-182. [PMID: 31293918 DOI: 10.14218/jcth.2018.00049] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
33 Romero-Gómez M, Rojas Á. Sofosbuvir modulates the intimate relationship between hepatitis C virus and lipids. Hepatology 2015;61:744-7. [PMID: 25345724 DOI: 10.1002/hep.27581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Chen YG, Lin TY, Dai MS, Lin CL, Hung Y, Huang WS, Kao CH. Risk of Peripheral Artery Disease in Patients With Carbon Monoxide Poisoning: A Population-Based Retrospective Cohort Study. Medicine (Baltimore) 2015;94:e1608. [PMID: 26448007 DOI: 10.1097/MD.0000000000001608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
35 Caballero-Marcos A, Romero-Cristóbal M, Puerto M, Fernández-Yunquera A, Dieguez L, Navarrete C, Clemente A, Diaz-Fontenla F, Catalán P, Rincón D, López-Baena JÁ, Bañares Cañizares R, Salcedo M. HCV eradication in recurrent hepatitis C after liver transplantation normalizes enhanced endothelial activation. Transpl Int 2021. [PMID: 34346111 DOI: 10.1111/tri.14000] [Reference Citation Analysis]
36 Piekarska A, Mamzer-Dachnowska A, Kasprzak JD, Peruga JZ, Kaszuba A, Berkan-Kawińska A. Prevalence of hepatitis C virus infection in patients hospitalised for ischemic heart disease versus controls - PRO-CARDIO-C study. Clin Exp Hepatol 2019;5:118-22. [PMID: 31501787 DOI: 10.5114/ceh.2019.84782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Ampuero J, Romero-Gómez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol. 2015;7:2214-2219. [PMID: 26380047 DOI: 10.4254/wjh.v7.i19.2214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
38 Calvaruso V, Craxì A. Why do I treat my patients with mild hepatitis C? Liver Int 2016;36 Suppl 1:7-12. [PMID: 26725891 DOI: 10.1111/liv.13011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
39 Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. Gastroenterology 2015;149:1345-60. [DOI: 10.1053/j.gastro.2015.08.035] [Cited by in Crossref: 221] [Cited by in F6Publishing: 192] [Article Influence: 36.8] [Reference Citation Analysis]
40 Bassendine MF, Nielsen SU, Bridge SH, Felmlee DJ, Sheridan DA, Packard CJ, Neely RD. Hepatitis C virus and atherosclerosis: A legacy after virologic cure? Clin Res Hepatol Gastroenterol 2017;41:25-30. [PMID: 27840032 DOI: 10.1016/j.clinre.2016.09.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]